Pharmaceutical Stocks To Add to Your Watchlist - August 15th

Key Points

• MarketBeat identified seven pharmaceutical stocks to watch, including Eli Lilly, Novo Nordisk, and Thermo Fisher Scientific, based on high trading volumes.
• Eli Lilly's stock is currently priced at $705.77, with a market cap of $667.98 billion and a recent 14% slide raising buy-the-dip speculation.
• Novo Nordisk's shares traded at $52.40 and are experiencing speculation about potential recovery from a recent decline, with a market cap of $233.94 billion.

Eli Lilly and Company, Novo Nordisk A/S, Thermo Fisher Scientific, D-Wave Quantum, Pfizer, Abbott Laboratories, and Precigen are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies engaged in researching, developing, manufacturing and marketing prescription drugs and biotechnological therapies. Their market value is driven by factors such as clinical-trial results, regulatory approvals, patent protections and overall healthcare demand. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

LLY traded up $22.84 during trading on Friday, hitting $705.77. The stock had a trading volume of 5,530,973 shares, compared to its average volume of 4,145,358. The company has a 50 day moving average price of $765.92 and a 200-day moving average price of $795.40. The firm has a market cap of $667.98 billion, a price-to-earnings ratio of 46.13, a P/E/G ratio of 0.93 and a beta of 0.44. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a one year low of $623.78 and a one year high of $972.53.

Read Our Latest Research Report on LLY

Novo Nordisk A/S (NVO)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

NVO traded up $1.45 on Friday, reaching $52.40. The stock had a trading volume of 11,225,304 shares, compared to its average volume of 11,424,236. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $139.74. The firm has a 50-day moving average of $65.40 and a 200-day moving average of $70.66. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $233.94 billion, a price-to-earnings ratio of 14.40, a price-to-earnings-growth ratio of 1.75 and a beta of 0.63.

Read Our Latest Research Report on NVO

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

NYSE TMO traded up $5.71 during trading hours on Friday, hitting $490.75. 1,163,118 shares of the company's stock were exchanged, compared to its average volume of 2,489,378. The stock has a 50-day simple moving average of $433.08 and a 200 day simple moving average of $461.44. Thermo Fisher Scientific has a 1-year low of $385.46 and a 1-year high of $627.88. The firm has a market cap of $185.31 billion, a price-to-earnings ratio of 28.38, a PEG ratio of 2.59 and a beta of 0.74. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Read Our Latest Research Report on TMO

D-Wave Quantum (QBTS)

D-Wave Quantum Inc. develops and delivers quantum computing systems, software, and services worldwide. The company offers Advantage, a fifth-generation quantum computer; Ocean, a suite of open-source python tools; and Leap, a cloud-based service that provides real-time access to a live quantum computer, as well as access to Advantage, hybrid solvers, the Ocean software development kit, live code, demos, learning resources, and a vibrant developer community.

D-Wave Quantum stock traded down $1.10 during mid-day trading on Friday, reaching $17.08. The stock had a trading volume of 32,638,439 shares, compared to its average volume of 68,441,570. The firm has a market capitalization of $4.99 billion, a PE ratio of -16.27 and a beta of 1.41. The stock's 50-day simple moving average is $16.78 and its 200-day simple moving average is $11.44. D-Wave Quantum has a fifty-two week low of $0.80 and a fifty-two week high of $20.56. The company has a debt-to-equity ratio of 0.05, a quick ratio of 42.86 and a current ratio of 42.99.

Read Our Latest Research Report on QBTS

Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Pfizer stock traded up $0.07 during mid-day trading on Friday, reaching $25.18. 20,502,695 shares of the company's stock were exchanged, compared to its average volume of 45,589,473. The firm has a market capitalization of $143.13 billion, a PE ratio of 13.39, a P/E/G ratio of 0.90 and a beta of 0.52. The business's fifty day simple moving average is $24.56 and its 200 day simple moving average is $24.46. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer has a one year low of $20.92 and a one year high of $30.43.

Read Our Latest Research Report on PFE

Abbott Laboratories (ABT)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Shares of NYSE ABT traded up $2.13 during mid-day trading on Friday, hitting $131.41. The company had a trading volume of 3,777,061 shares, compared to its average volume of 6,878,398. Abbott Laboratories has a 1 year low of $110.33 and a 1 year high of $141.23. The stock's 50-day moving average price is $131.44 and its 200-day moving average price is $131.15. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $228.72 billion, a price-to-earnings ratio of 16.47, a P/E/G ratio of 2.45 and a beta of 0.70.

Read Our Latest Research Report on ABT

Precigen (PGEN)

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.

PGEN stock traded up $1.31 during mid-day trading on Friday, hitting $3.16. 153,328,633 shares of the stock were exchanged, compared to its average volume of 2,984,121. Precigen has a 12 month low of $0.65 and a 12 month high of $3.49. The business has a fifty day moving average price of $1.65 and a 200 day moving average price of $1.58. The stock has a market capitalization of $941.88 million, a price-to-earnings ratio of -7.48 and a beta of 1.87.

Read Our Latest Research Report on PGEN

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.